文献速递帕金森病与运动障碍认知障碍与痴呆

脑脊液神经丝轻链与磷酸化tau181预测进行性核上性麻痹疾病进展

CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.
PubMed 文献 · Neurology · 2017-12-27

本研究在50例进行性核上性麻痹(PSP)患者中比较基线脑脊液β-淀粉样蛋白1-42、tau、磷酸化tau181(p-tau)和神经丝轻链(NfL)预测52周临床、神经心理和MRI区域脑体积变化的能力,并在141例患者中分析血浆NfL。结果显示较高的脑脊液NfL预测PSPRS和SEADL更快速下降,较低的脑脊液p-tau预测PSPRS更快速下降,脑脊液NfL/p-tau比值预测PSPRS变化优于单独p-tau或NfL。

要点

  • 脑脊液NfL较高预测52周PSPRS和SEADL更快速下降。
  • 脑脊液p-tau较低预测52周PSPRS更快速下降。
  • 脑脊液NfL/p-tau比值预测PSPRS变化优于单独p-tau或NfL。

核心结论

  • 脑脊液p-tau和NfL均与PSP疾病严重程度和进展速率相关。
  • p-tau与疾病严重程度呈负相关,提示PSP中tau病理机制可能与阿尔茨海默病不同。

研究设计与样本

  • 研究纳入50例PSP患者,比较基线脑脊液β-淀粉样蛋白1-42、tau、p-tau和NfL预测52周临床、神经心理和MRI区域脑体积变化。
  • 采用线性混合效应模型控制年龄、性别和基线疾病严重程度,并用Fisher F密度曲线比较效应量。
  • 另在141例患者中分析单分子阵列测量的血浆NfL。

主要发现

  • 较高的脑脊液NfL浓度预测52周PSPRS更快速下降(p=0.004,FDR校正)和SEADL更快速下降(p=0.008)。
  • 较低的基线脑脊液p-tau预测52周PSPRS更快速下降(p=0.004)。
  • 较高的脑脊液tau浓度预测52周SEADL更快速下降(p=0.004)。
  • 脑脊液NfL/p-tau比值预测PSPRS变化优于单独p-tau(p=0.003)或NfL(p=0.001)。
  • 较高脑脊液NfL和血浆NfL均与更严重的小脑上脚萎缩相关(固定效应p≤0.029和p=0.008)。

关键数值与推荐

  • 脑脊液NfL预测PSPRS下降的交互作用p=0.004(FDR校正)。
  • 脑脊液NfL预测SEADL下降的交互作用p=0.008。
  • 脑脊液p-tau预测PSPRS下降的交互作用p=0.004。
  • 脑脊液NfL/p-tau比值预测PSPRS变化优于p-tau(p=0.003)或NfL(p=0.001)。

临床怎么用

  • 脑脊液NfL和p-tau可作为PSP疾病进展的预测生物标志物。
  • 脑脊液NfL/p-tau比值可能提高对PSP进展的预测能力。
  • 血浆NfL与脑脊液NfL均与PSP小脑上脚萎缩相关,便于临床监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the ability of CSF biomarkers to predict disease progression in progressive supranuclear palsy (PSP). METHODS: We compared the ability of baseline CSF β-amyloid1-42, tau, phosphorylated tau 181 (p-tau), and neurofilament light chain (NfL) concentrations, measured by INNO-BIA AlzBio3 or ELISA, to predict 52-week changes in clinical (PSP Rating Scale [PSPRS] and Schwab and England Activities of Daily Living [SEADL]), neuropsychological, and regional brain volumes on MRI using linear mixed effects models controlled for age, sex, and baseline disease severity, and Fisher F density curves to compare effect sizes in 50 patients with PSP. Similar analyses were done using plasma NfL measured by single molecule arrays in 141 patients. RESULTS: Higher CSF NfL concentration predicted more rapid decline (biomarker × time interaction) over 52 weeks in PSPRS (p = 0.004, false discovery rate-corrected) and SEADL (p = 0.008), whereas lower baseline CSF p-tau predicted faster decline on PSPRS (p = 0.004). Higher CSF tau concentrations predicted faster decline by SEADL (p = 0.004). The CSF NfL/p-tau ratio was superior for predicting change in PSPRS, compared to p-tau (p = 0.003) or NfL (p = 0.001) alone. Higher NfL concentrations in CSF or blood were associated with greater superior cerebellar peduncle atrophy (fixed effect, p ≤ 0.029 and 0.008, respectively). CONCLUSIONS: Both CSF p-tau and NfL correlate with disease severity and rate of disease progression in PSP. The inverse correlation of p-tau with disease severity suggests a potentially different mechanism of tau pathology in PSP as compared to Alzheimer disease.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Rojas JC, Bang J, Lobach IV, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2017. PMID: 29282336. doi:10.1212/WNL.0000000000004859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。